Compare iShares International Treasury Bond ETF (IGOV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs ResMed Inc. — how do they compare? iShares International Treasury Bond ETF trades at $41.19, while ResMed Inc. trades at $225.56 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| IGOV | RMD | |
|---|---|---|
52-Week High | $43.09 | $293.73 |
52-Week Low | $40.35 | $182.82 |
Market Cap | — | $32.61B |
Sector | — | Health |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, an iShares International Treasury Bond ETF, trades at $41.21, showing minimal daily movement with a 0.05% gain. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights significant downside risk due to its high duration exposure amid global inflationary pressures and geopolitical tensions, which could lead to capital losses as benchmark rates rise.
The outlook for IGOV is clouded by macroeconomic headwinds; rising global interest rates pose a substantial risk to its bond holdings. Investment opportunity exists for those seeking international treasury exposure, but caution is warranted due to sensitivity to rate changes and ongoing energy-related market volatility.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
